Arvinas reported Phase 1 multiple‑dose data showing ARV‑102, an oral PROTAC degrader targeting LRRK2, achieved approximately 50% or greater reduction of LRRK2 protein in cerebrospinal fluid at all dose levels by day 14 and maintained reductions through day 28 in Parkinson’s disease patients. The randomized, placebo‑controlled cohort tested daily doses of 20–80 mg and demonstrated dose‑dependent CSF exposure consistent with brain penetration. Investigators also reported reductions in endolysosomal and neuroinflammatory biomarkers associated with LRRK2 expression, and ARV‑102 was well tolerated across doses in the small Phase 1 cohort. Data were presented at the AD/PD 2026 conference. Arvinas said the results support further development of ARV‑102 across neurodegenerative diseases featuring lysosomal dysfunction, and the findings are among the first clinical signals of central target degradation for a PROTAC in neurodegeneration.